Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L Moertel

Clinical investigators discuss available data guiding the management of biliary tract cancers.  CME information and select publications here.

Clinical investigators discuss available data guiding the management of neuroendocrine tumors.  CME information and select publications here.

Dr Christopher L Moertel from the University of Minnesota in Minneapolis discusses the clinical presentation of and optimal management strategies for plexiform neurofibromas and malignancies associated with neurofibromatosis type 1. CME information and select publications here.

Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston and Dr Jeffrey Meyerhardt from Dana-Farber Cancer Institute in Boston summarize the most clinically relevant research findings and data presented over the past year for patients with colorectal cancer. CME information and select publications here.

Dr John Bridgewater from the UCL Cancer Institute in London, United Kingdom, discusses patient cases and summarizes current treatment approaches for cholangiocarcinoma and other biliary tract cancers. CME information and select publications here.

Dr Arvind Dasari, Dr Van Morris, Dr Jenny Seligmann, Prof Eric Van Cutsem and moderator Dr Christopher Lieu summarize research findings guiding the application of biomarker-driven therapy for patients with colorectal cancers during a session at the 2025 ASCO Gastrointestinal Cancers Symposium. CME information and select publications here.

Dr Anthony El-Khoueiry, Dr Richard Finn, Dr Aiwu Ruth He, Dr Stacey Stein and moderator Dr Stephen “Fred” Divers discuss data from the 2025 ASCO GI meeting and other published studies guiding the care of patients with hepatocellular carcinoma.CME information and select publications here.

Dr Christopher Lieu shares his perspectives on the evolving therapeutic landscape for patients with colorectal and gastroesophageal cancers.

Dr Daneng Li shares his perspectives on the evolving therapeutic landscape for patients with hepatobiliary cancers.

Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers.